Appl. No. 10/849,282 Amendment dated July 25, 2007 Reply to Office Action of February 23, 2007

Amendments to the Claims:

This listing of claims replaces all prior versions and listings of claims in the application.

Listing of Claims:

Claim 1. (Currently Amended): A topical water-in-oil pharmaceutical cream composition for the treatment of inflammation comprising:

- a) 0.01 to 0.25 percent Mometasone Furoate;
- b) 10 to 30 percent propylene glycol;
- c) 1.0 to 5 percent water;
- d) 2.0 to 10.0 percent white wax;
- e) 4.0 to 12.0 percent of a lipophilic surfactant having an HLB value of less than 6;
- f) 0.7 to 4.0 percent of a hydrophilic surfactant having an HLB value of greater than 10;
- g) 0.2 to 2.0 percent Titanium dioxide;
- h) 5.0 to 20.0 percent aluminum starch octenylsuccinate;
- i) 40 to 70 percent white petrolatum; and
- j) sufficient acid to adjust the pH of the water wherein said composition has a viscosity of about 400,000 to about 900,000 centipoise,

wherein the cream composition is effective for treating inflammation.

Claim 2. (Original): The topical pharmaceutical composition of claim 1 wherein the lipophilic surfactant is selected from the group consisting of propylene glycol stearate, ethylene glycol monolaurate, ethylene glycol monolaurate and glyceryl monoricinolate.

Claim 3. (Original): The topical pharmaceutical composition of claim 1 wherein the hydrophilic surfactant is selected from the group consisting of stearyl alcohol and ceteareth-20, polyethylene

Appl. No. 10/849,282 Amendment dated July 25, 2007 Reply to Office Action of February 23, 2007

glycol monolaurate, polyethylene glycol distearate, polyoxyethylene cetyl alcohol, polyoxyethylene sorbitan monostearate and polyoxyethylene sorbitan monooleate.

Claim 4. (Original): The topical pharmaceutical composition of claim 1 wherein the acid utilized to adjust the pH of the water is selected from the group consisting of phosphoric acid, hydrochloric acid, and acetic acid.

Claim 5. (Currently Amended): A topical water-in-oil pharmaceutical cream composition for the treatment of inflammation comprising:

- a) 0.10 percent Mometasone Furoate;
- b) 22.50 percent propylene glycol;
- c) 2.59 percent water;
- d) 3 percent white wax;
- e) 6 percent of propylene glycol stearate;
- f) 1.35 percent of ceteareth-20;
- g) 2.0 percent Titanium dioxide;
- h) 10 percent aluminum starch octenylsuccinate;
- i) 51.8 percent white petrolatum; and
- j) sufficient phosphoric acid to adjust the pH of the water to wherein said composition has a viscosity of about 650,000 to about 825,000 centipoise, wherein the cream composition is effective for treating inflammation.

Claim 6. (Withdrawn): A method for treating a patient suffering from inflammation of the skin, comprising:

applying a layer of the topical water-in-oil pharmaceutical cream of claim 1 to the inflamed skin of the patient; and

allowing the layer of the topical water-in-oil pharmaceutical cream to remain on the skin for a

Appl. No. 10/849,282 Amendment dated July 25, 2007

Reply to Office Action of February 23, 2007

duration effective to reduce the inflammation.

Claim 7. (Withdrawn): The method of claim 6, wherein the topical water-in-oil pharmaceutical

cream does not irritate the skin.

Claim 8. (Withdrawn): A method for treating a patient suffering from inflammation of the skin,

comprising:

applying a layer of about 10 µl of the topical water-in-oil pharmaceutical cream of claim 1 to

the inflamed skin of the patient; and

allowing the layer of the topical water-in-oil pharmaceutical cream to remain on the skin for

about 1 hour.

Claim 9. (Withdrawn): The method of claim 8, wherein the topical water-in-oil pharmaceutical

cream does not irritate the skin during the time the topical water-in-oil pharmaceutical cream remains

on the skin.